Having trouble accessing articles? Reset your cache.

Editas shows better gene editing using Cas9 alternative for sickle cell, thalassemia

Editas preclinical data suggest Cas12a better than Cas9 for edited cell therapy for sickle cell, thalassemia

Editas is using an alternative to Cas9 to develop a differentiated sickle cell and β thalassemia CRISPR gene therapy. Preclinical data presented Monday at ASH suggest that ex vivo gene editing could be more effective via Cas12a.

Editas Medicine

Read the full 386 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE